$-0.09 EPS Expected for Concordia International Corp. (CXR)

July 14, 2018 - By Palma Niemeyer

Concordia International Corp. (TSE:CXR) Logo

Analysts expect Concordia International Corp. (TSE:CXR) to report $-0.09 EPS on August, 10.They anticipate $0.35 EPS change or 134.62 % from last quarter’s $0.26 EPS. After having $-0.24 EPS previously, Concordia International Corp.’s analysts see -62.50 % EPS growth. The stock increased 3.85% or $0.01 during the last trading session, reaching $0.27. About 59,809 shares traded. Concordia International Corp. (TSE:CXR) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $13.85 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.